MGI Tech Showcases Full-Stack Life Science Tools at CSGCT 2025 as a Leading Global Enabler

MGI Tech Co., Ltd.

Abbreviation: MGI

Booth Number: B02

MGI Tech Co., Ltd. (hereinafter referred to as “MGI”) adheres to the philosophy of “Innovative Intelligent Manufacturing Leading Life Sciences.” It focuses on the research and development of underlying technologies and product innovation for core tools centered around the “reading, writing, and storing” aspects of the central dogma of life sciences. MGI continuously provides users with comprehensive system solutions that cover all scenarios and the full lifecycle in life science research and applications. Committed to leveraging genomics-based multi-omics technologies to drive breakthroughs in scientific research and facilitate clinical translation, MGI collaborates with upstream and downstream partners in the life sciences and biotechnology industries to build an open, cooperative, and win-win industrial ecosystem.

MGI was founded in 2016. As of December 31, 2024, its business presence spans more than 110 countries and regions across six continents. Globally, MGI has established nine R&D centers, seven production bases, nine international warehouses, and 13 customer experience centers, serving a cumulative total of over 3,300 users. As a provider of core tools for life sciences, MGI has not only achieved comprehensive strategic coverage of gene sequencing products across three technological pathways—“excited light,” “self-luminescence,” and “non-luminescence”—but is also the world’s first company to simultaneously offer commercially mass-produced short-read and long-read sequencing products.

To promote ChinaCGTAmid technological breakthroughs, industrial convergence, policy alignment, and international cooperation in the field, China’s cell and gene therapy (CGT) industry is advancing to the forefront of global competition, giving rise to the China Society for Gene and Cell Therapy (CSGCT) Conference.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, and applications in the global cell and gene therapy field, provide insights into market access, highlight high-quality collaborative projects, and facilitate matchmaking between overseas investors and investment opportunities. It aims to build a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global supply chain.

The conference closely addressed the industry's hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Small Nucleic Acid Drugs, Gene Editing, Oncolytic Viruses, and Tumor Vaccines, as well as CMC and Testing, AI-Driven Drug Discovery, Investment and Financing, and BD Matchmakingextensive coverage across the entire industrial chain.

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.